Lipoprotein(a) — Latest Guidelines (2026 Update)

1. Who Should Be Tested? (Major Change 🔑)

All adults should have Lp(a) measured at least once in lifetime (ACC/AHA 2026, ESC/EAS 2025)

Earlier selective testing → now shift toward universal screening

Strong indications:

Premature ASCVD

Family history of early CAD

Recurrent events despite optimal LDL

Calcific aortic stenosis

👉 Lp(a) is genetically determined & stable, so one-time test is usually enough

---

2. Risk Thresholds (Important Exam Point)

Lp(a) Level Interpretation

<30 mg/dL Normal

30–49 mg/dL Intermediate

≥50 mg/dL (≥125 nmol/L) High / Risk-enhancing

≥250 nmol/L Very high risk (~2× ASCVD risk)

≥50 mg/dL is now universally accepted cutoff across guidelines

Higher levels → progressively higher risk (no strict threshold effect)

---

3. Role in Risk Stratification

Lp(a) is now considered:

✅ Independent causal risk factor for:

Atherosclerotic cardiovascular disease (ASCVD)

Stroke

Calcific aortic stenosis

✅ Risk-enhancing factor in guidelines:

Influences statin decision in borderline/intermediate risk

Explains “residual risk” despite normal LDL

---

4. Management Strategy (Key Clinical Concept)

⚠️ No widely approved specific Lp(a)-lowering drug yet

Current approach:

1. Aggressive control of all modifiable risk factors

LDL-C (primary target)

BP, diabetes, smoking

Lifestyle optimization

2. LDL-C targets become stricter

High risk: <70 mg/dL

Very high risk: <55 mg/dL

3. Pharmacologic options

Statins → do NOT lower Lp(a) (may increase slightly)

PCSK9 inhibitors

↓ Lp(a) ~20–30%

Used for overall risk reduction

Ezetimibe / Bempedoic acid → LDL-focused

4. Lipoprotein apheresis

Only approved therapy in selected high-risk patients

↓ Lp(a) significantly (25–70%)

---

5. Emerging Therapies (Very Important 🚀)

RNA-based drugs (antisense / siRNA):

Pelacarsen

Olpasiran

👉 Show up to 80–90% Lp(a) reduction in trials

👉 Outcome trials ongoing → may change guidelines soon

---

6. Special Recommendations

Cascade screening for family members (genetic nature)

Consider:

Coronary calcium scoring (risk refinement)

Aspirin:

Selected high-risk patients with high Lp(a) (case-based)

---

🔴 Key Takeaways (Exam + Clinical Practice)

Measure Lp(a) once in every adult

≥50 mg/dL = risk enhancer

No direct treatment yet → focus on aggressive LDL lowering

PCSK9 inhibitors + apheresis in selected patients

Future = RNA therapies will change management

Comments

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚 in Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts. The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

Learn Echocardiography | Standard Protocol for Performing Comprehensive Echocardiogram | Explained with Images and Videos

If you are just starting to learn echocardiography, you will find that learning the full echo examination protocol will be immensely useful. The full protocol will provide a solid foundation for your career in echo. I personally found that once I could execute the standard protocol flawlessly, I was able to add and refine additional echo scanning skills while deepening my understanding of the purpose of each echo image. The echo protocol illustrated in this article is the same one we currently use for all our patients in the hospital and meets or exceeds the standards of American Society of Echocardiography (ASE) for an adult echocardiography examination. The protocol presented here is meant as a guideline and does not cover every aspect (such as off axis views) of an echo examination. Also other hospitals will probably have slight variations of this protocol depending on the lab's needs, which is normal. This article's main purpose is to provide a solid foundation for ...

Dr. Usman's Cardiology Notes

Search This Blog